Risk Stratification of Sudden Cardiac Death by Evaluating Myocardial Sympathetic Nerve Activity Using Iodine-123 Metaiodobenzylguanidine Scintigraphy in Patients with Chronic Heart Failure and Dilated Cardiomyopathy

A Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) has proven the efficacy of prophylactic implantable cardioverter defibrillator (ICD) use for chronic heart failure pa‐ tients without sustained ventricular tachycardia (SVT) and a history of ventricular fibril‐ lation, not restricted in those with myocardial infarction [1]. Since ICD is an expensive device, risk stratification is required to identify heart failure patients at high risk for sud‐ den death without SVT.